{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:38:58Z","timestamp":1791380338321,"version":"4.3.3"},"reference-count":9,"publisher":"MedWorks Media","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>There is much uncertainty on continuing antipsychotics where a patient has an asymptomatic rise in creatine kinase. This case report describes a patient in his late 20s and early 30s with an established diagnosis of schizophrenia. He experienced multiple asymptomatic rises in creatine kinase (CK) when treated with numerous antipsychotics, which led to them being discontinued. Eventually, successful treatment was undertaken when clozapine was trialled. This led to improved quality of life scores when objectively measured, as well as good tolerance with no physical health sequelae. In conclusion, we recommend that clozapine is considered when other antipsychotic medications lead to elevated CK levels or neuroleptic malignant syndrome.<\/jats:p>","DOI":"10.64719\/pb.4524","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:23:34Z","timestamp":1761045814000},"page":"85-93","source":"Crossref","is-referenced-by-count":1,"title":["Raised Creatine Kinase with Numerous Antipsychotics Responded to Clozapine"],"prefix":"10.64719","volume":"55","author":[{"given":"Michael","family":"Dixon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Venters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","unstructured":"Taylor D, Barnes TE, Young AH. The Maudsley Prescribing Guidelines in Psychiatry. Wiley Blackwell."},{"key":"ref2","unstructured":"Manu P, Flanaghan RJ, Ronaldson KJ. Life-threatening effects of antipsychotic drugs. 2016 Elsevier."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Kim EJ, Wierzbicki AS. Investigating raised creatine kinase. BMJ. 2021;373:n1486. doi: 10.1136\/bmj.n1486.. Published 23 June 2021.","DOI":"10.1136\/bmj.n1486"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Voros V, Osvath P, Fekete S et al. Elevated serum creatine kinase levels in psychiatric practice: differential diagnosis and clinical significance: A brief, practical guideline for clinicians. International Journal of Psychiatry in Clinical Practice. 2008;12(2):147\u2013150. 4p. 1 Diagram, 2 Charts.","DOI":"10.1080\/13651500701784930"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Langford A. The National Psychosis Unit: curing the incurable. The Lancet Psychiatry. 2015;2(11):965\u2013966.","DOI":"10.1016\/S2215-0366(15)00460-5"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Keetharuth A, Brazier J, Connell J, Bjorner J, Carlton J, Taylor-Buck E, Ricketts T, McKendrick K, Browne J, Croudace T, Barkham M. Recovering Quality of Life (ReQOL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties. The British Journal of Psychiatry. 2018;212(1):42\u201349.","DOI":"10.1192\/bjp.2017.10"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Laoutidis ZG, Kioulos KT. Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice. Psychopharmacology (Berl). 2014;231(22):4255\u20134270. doi: 10.1007\/s00213-014-3764-2. Epub 2014 Oct 16. PMID: 25319963.","DOI":"10.1007\/s00213-014-3764-2"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Zacharias GL, Kiouslos KT. Antipsychotic-induced elevation of creatinine kinase: a systematic review of the literature and recommendations for clinical practice. Psychopharmacology. 2014;213:4255\u20134270.","DOI":"10.1007\/s00213-014-3764-2"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Melkersson K. Serum creatine kinase levels in chronic psychosis patients\u2014a comparison between atypical and conventional antipsychotics. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2006;30(7):1277\u20131282.","DOI":"10.1016\/j.pnpbp.2006.04.025"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:33:25Z","timestamp":1791315205000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/raised-creatine-kinase-with-numerous-antipsychotics-responded-to-clozapine\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4524","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}